Vir Biotechnology (VIR) revenue breakdown
By product, License and collaboration revenue is the largest at 92% of fiscal 2025 revenue, growing 30% a year over 2 years.
Revenue by product
Fiscal years, as Vir Biotechnology reports them in its 10-K filings; fiscal 2025 total $69M.
| Products | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|
| License and collaboration revenue | — | — | $37M | $61M | $63M | 92% |
| Other revenue | — | — | $2M | $2M | $3M | 5% |
| Grant revenue | $8M | $35M | $47M | $10M | $2M | 3% |
| Collaboration revenue | $917M | $1.5B | — | — | — | — |
| Contract revenue | $170M | $53M | — | — | — | — |
| License revenue from a related party | — | $22M | — | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for VIR.
Open VIR in InvestinglyQuestions
Where does Vir Biotechnology make its money?
In fiscal 2025, by product: License and collaboration revenue $63M, Other revenue $3M, Grant revenue $2M.
From Vir Biotechnology's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.